Form 8-K Relay Therapeutics, Inc. For: Sep 09
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St slips as Gulf tensions send oil to over six-week high
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Trump says Canada's Bombardier must build jets in US or lose market access
- Wall St slips as Gulf tensions send oil to over six-week high
- European shares subdued as surging crude sharpens focus on ECB rate path
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Goldman Sachs Reinstates Relay Therapeutics (RLAY) at Buy
September 9, 2024 4:47 PM EDTGoldman Sachs analyst Salveen Richter reinstates coverage on Relay Therapeutics (NASDAQ: RLAY) with a Buy rating and a price target of $20.00.
The analyst comments "Given positive Ph2 data of selective PI3K inhibitor RLY-2608 + fulvestrant in PI3K-mutated HR+/HER2- breast cancer and planned Ph3 initiation in 2025, we reinstate RLAY with a Buy rating and $20 price... More
TD Cowen Out Positive on Relay Therapeutics (RLAY), Shares Up ~53%, 'we are constructive on Ph3 success based on today's data'
September 9, 2024 3:20 PM EDTTD Cowen analyst Yaron Werber reiterated a Buy rating on Relay Therapeutics (NASDAQ: RLAY).
The analyst comments "Our Take: RLY-2608 Impresses With Unparalleled 9.2 Months mPFS, 33% ORR, And Minimal Hyperglycemia Moving into Ph3 Vs AZN Truqap This morning, Relay announced positive interim data for the RLY-2608 + fulvestrant doublet in HR+/HER2- locally advanced or metastatic breast cancer showing unmatched efficacy on PFS and ORR, and continued differentiation on safety vs both approved therapies (AZN's Truqap & NVS' Piqray). In our view, this data is highly encouraging and... More
Relay Therapeutics (RLAY) Shares Gain ~51%, PT Raised to $17 at Barclays
September 9, 2024 3:03 PM EDTBarclays analyst Peter Lawson raised the price target on Relay Therapeutics (NASDAQ: RLAY) to $17.00 (from $14.00) while maintaining a Overweight rating.
The analyst comments "We increase our probability of success for RLY-2608 in advanced HR+/HER2- breast cancer and increase our penetration rate... More
